Physician profile
Bryan Griffin
NPI 1851476998
$704.79
in general payments reported to CMS, 2019-2025
10 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.21 · 2021: $120 · 2022: $17.27 · 2023: $171 · 2024: $57.82 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $132.00 | 2023 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $123.97 | 2025 | Cobenfy |
| Luye Pharma (USA) LTD. | $121.17 | 2025 | Erzofri Extended-Release |
| Viiv Healthcare Company | $120.26 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.25 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $54.43 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $23.76 | 2023 | Vivitrol |
| Neurocrine Biosciences, INC. | $23.47 | 2025 | |
| Abbvie INC. | $17.27 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.